How Cell Therapy's Fundamentally Different Model Impacts Patients

This talk will discuss the current autologous CAR T market from the perspective of authorized and marketed products. It will show the manufacturing workflow of an autologous CAR T therapy, touch on the history of these therapies, and look at how the workflow compares to biologics manufacturing—both where it differs and where it has borrowed from bioprocessing. Bill will also give examples of how customers are using our products to enable delivery of cell therapies to patients.